Skip to main content
. 2025 Aug 22;11(34):eadx9763. doi: 10.1126/sciadv.adx9763

Fig. 5. The periosteum layer increases thickness after PEG-peptide plasmid miR-200a treatments.

Fig. 5.

(A) H&E-stained sections of P21 WT and untreated and treated Twist1+/− mice. The yellow brackets outline the periosteum layer, which is thinner in Twist1+/− control and EV-treated mice compared to that in WT. However, in miR-200a–treated Twist1+/− mice, the periosteum layer is thicker compared to all mice. (B) Quantitation of periosteum thickness (eight mice were analyzed for each treatment group, n = 8, *P < 0.05 and ****P < 0.0001). (C) H&E-stained sections of P21 WT and untreated and treated Twist1+/− mice. The yellow brackets outline the dura mater layer, which is unchanged in Twist1+/− control, EV-treated, and miR-200a–treated mice compared to that in WT. (D) Quantitation of dura mater thickness. n = 8 (eight mice were analyzed for each treatment group); n.s., not statistically significant.